Related Experiment Video
Updated: Jun 14, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation
Abby Mercer Tyson1, Wendy E Gay
1Riverside Methodist Hospital, Columbus, OH 43214, USA. atyson2@ohiohealth.com
The Annals of Pharmacotherapy
|April 8, 2010
Summary
Dexrazoxane effectively treated doxorubicin extravasation, preventing tissue damage and chemotherapy delays. Institutions should stock this antidote or arrange sharing to ensure timely access for anthracycline extravasation emergencies.
Area of Science:
- Oncology
- Pharmacology
- Patient Safety
Background:
- Doxorubicin extravasation poses a significant risk of tissue damage and treatment interruption in cancer patients.
- Prompt intervention is crucial to mitigate adverse effects following extravasation.
- Dexrazoxane is an FDA-approved antidote for anthracycline extravasations.
Observation:
- A breast cancer patient experienced doxorubicin extravasation during adjuvant therapy.
- Treatment with dexrazoxane was initiated within 6 hours of the extravasation event.
- The patient completed a full course of dexrazoxane without complications, avoiding chemotherapy delays.
Findings:
- Dexrazoxane administration successfully minimized tissue damage.
- Expedient treatment with dexrazoxane prevented significant delays in the patient's planned chemotherapy course.
- The patient successfully completed her full chemotherapy regimen.
Implications:
- Dexrazoxane is a vital antidote for anthracycline extravasations, preserving treatment continuity.
- Healthcare facilities must establish protocols for rapid access to dexrazoxane.
- Collaborative strategies, like inter-institutional cost sharing, can address the financial challenges of stocking dexrazoxane.
